What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to provide the required historical financial statements of St. Jude Medical, Inc., as part of Abbott Laboratories' ongoing acquisition of the company. These financials are necessary for regulatory compliance and for investors to assess the acquired business.

What periods do the St. Jude Medical financial statements cover?

The filing includes audited consolidated financial statements for St. Jude Medical for the years ended January 2, 2016, January 3, 2015, and December 28, 2013. It also includes condensed consolidated financial statements for the nine-month periods ended October 1, 2016, and October 3, 2015.

Why are these financial statements being filed now, months after the acquisition was announced?

SEC regulations (specifically Rule 3-05 of Regulation S-X) require acquiring companies to file the historical financial statements of a significant acquired business with the SEC. This filing provides those required historical financials of St. Jude Medical, allowing investors to analyze the target company's performance and financial position before the acquisition is finalized.

Does this filing provide any updates on the deal terms or closing date of the St. Jude Medical acquisition?

No, this 8-K filing does not provide specific updates on the deal terms or the expected closing date of the acquisition. Its focus is solely on supplying the necessary historical financial statements of St. Jude Medical as stipulated by SEC rules.

ABT 8-K SEC Disclosure — Nov 17, 2016

Summary

Abbott Laboratories (ABT) filed an 8-K on November 16, 2016, primarily to provide updated financial information related to its previously announced acquisition of St. Jude Medical, Inc. The filing includes historical financial statements for St. Jude Medical as required by SEC regulations for significant acquisitions. This information is crucial for investors to assess the financial health and potential impact of the St. Jude Medical business on Abbott's consolidated financial position. The inclusion of St. Jude Medical's audited financial statements for the years ended January 2, 2016, January 3, 2015, and December 28, 2013, along with interim condensed financial statements for the nine months ended October 1, 2016, allows for a detailed examination of the acquired entity's performance and balance sheet. Investors should review these exhibits to understand the scale and financial characteristics of St. Jude Medical, which will be integrated into Abbott's operations.

Key Highlights

1Abbott Laboratories is providing St. Jude Medical's historical financial statements in compliance with SEC Rule 3-05 for its pending acquisition.
2The filing includes audited consolidated balance sheets for St. Jude Medical as of January 2, 2016 and January 3, 2015.
3Audited consolidated statements of earnings, comprehensive income, shareholders' equity, and cash flows for St. Jude Medical for fiscal years 2016, 2015, and 2013 are included.
4Condensed consolidated financial statements for St. Jude Medical for the nine months ended October 1, 2016, and October 3, 2015, are provided.
5These financial statements are crucial for investors to evaluate the financial profile of St. Jude Medical prior to its integration with Abbott.
6The filing confirms the ongoing progress of the acquisition of St. Jude Medical, which was initially announced on April 26, 2016.

ABBOTT LABORATORIES 8-K Report, Corporate Update (Nov 17, 2016)

Summary

Key Highlights

Frequently Asked Questions